{"id":791080,"date":"2024-11-27T07:33:17","date_gmt":"2024-11-27T12:33:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/"},"modified":"2024-11-27T07:33:17","modified_gmt":"2024-11-27T12:33:17","slug":"prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/","title":{"rendered":"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WILMINGTON, Del., Nov.  27, 2024  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=baDBceXxvk0INmD2PCULDRECJ2ghXRLH44nIVXVF8KcRf2iAUvEU_KrxQITxAJqxKa2uTlpGT3UlphHA1YF5AdtLl4CJ0wnxUgLTRYUnyfI=\" rel=\"nofollow\" target=\"_blank\">Prelude Therapeutics Incorporated<\/a> (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024.<\/p>\n<p>On Monday, December 2, at 11:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat.<\/p>\n<p>A live webcast of the fireside chat can be accessed on the Company\u2019s website under <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iyLPjdyIBaE0nKVta_D23ft3dDV8MT8_f-WUl54LiQPvFweRAAHDJHJZUFc8hwo_nfDT_XGOR44WKO08vwTsUUh-gCKzeb_3I7iacmEFcplvVfbFPwh0XptVthRiJyA5XWQ0jsHUdt-48U-XuN45TMv9ihe24hFN67CSz5CZeDQ=\" rel=\"nofollow\" target=\"_blank\">Events and Presentations<\/a>. The recording will be archived and available on the Company\u2019s website for 90 days.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>About Prelude Therapeutics<\/em><br \/>\n        <\/strong><br \/>\n        <em>\u00a0<\/em>\n      <\/p>\n<p>Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong>\u00a0<br \/>Robert Doody <br \/>Senior Vice President, Investor Relations\u00a0<br \/>Prelude Therapeutics<br \/>484.639.7235<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CyUhwbS4_BubX-5oy_pYPt4TtfNTd8T3AbXVeMQhTd19IsLiFMwtX52IPYNoC7kwzc1treeJoj9s_dyXeHjWVLBWKDJFT5npKBv17ouciZo=\" rel=\"nofollow\" target=\"_blank\">RDoody@preludetx.com<\/a> \u00a0<br \/>\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmQ1MTU4MDctMDBmZS00MTBjLTlhNjgtMGMyNjE4MTY5NDM5LTEyMTM4NzY=\/tiny\/Prelude-Therapeutics-Incorpora.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024. On Monday, December 2, at 11:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company\u2019s website under Events and Presentations. The recording will be archived and available on the Company\u2019s website for 90 days. About Prelude Therapeutics \u00a0 Prelude Therapeutics is a leading precision oncology company developing innovative medicines &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791080","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024. On Monday, December 2, at 11:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company\u2019s website under Events and Presentations. The recording will be archived and available on the Company\u2019s website for 90 days. About Prelude Therapeutics \u00a0 Prelude Therapeutics is a leading precision oncology company developing innovative medicines &hellip; Continue reading &quot;Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-27T12:33:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit\",\"datePublished\":\"2024-11-27T12:33:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/\"},\"wordCount\":224,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/\",\"name\":\"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=\",\"datePublished\":\"2024-11-27T12:33:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/","og_locale":"en_US","og_type":"article","og_title":"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Market Newsdesk","og_description":"WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024. On Monday, December 2, at 11:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company\u2019s website under Events and Presentations. The recording will be archived and available on the Company\u2019s website for 90 days. About Prelude Therapeutics \u00a0 Prelude Therapeutics is a leading precision oncology company developing innovative medicines &hellip; Continue reading \"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2024-11-27T12:33:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit","datePublished":"2024-11-27T12:33:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/"},"wordCount":224,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/","name":"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=","datePublished":"2024-11-27T12:33:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MDYzNCM2NjEyMTE5IzIyMDIzMjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791080"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791080\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}